Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	39.29	61.64	9.74	15.56
Short-Term Investments	87.07	12.02	0.25	0.55
Cash & Short-Term Investments	126.35	73.66	9.99	16.11
Cash Growth	53.41%	637.44%	-37.98%	-
Other Current Assets	2.86	0.47	0.38	0.39
Total Current Assets	129.21	74.14	10.37	16.49
Net Property, Plant & Equipment	0.44	0.74	0.16	0.25
Other Long-Term Assets	3.58	2.64	0.01	0.01
Total Assets	133.23	77.51	10.54	16.76
Accounts Payable	4.44	2.3	1.04	0.26
Accrued Expenses	5.86	2.29	0.24	0.24
Current Portion of Leases	0.43	0.34	0.11	0.1
Total Current Liabilities	10.74	4.93	1.38	0.6
Long-Term Leases	0.12	0.44	0.05	0.16
Other Long-Term Liabilities	-	0.03	0	0.02
Total Long-Term Liabilities	0.12	0.47	0.05	0.18
Total Liabilities	10.85	5.39	1.43	0.78
Additional Paid-in Capital	220.62	3.68	2.94	2.61
Accumulated Other Comprehensive Income	0.08	-	-	-
Retained Earnings	-98.32	-58.33	-37.74	-30.53
Total Common Shareholders' Equity	122.38	-54.64	-34.8	-27.92
Minority Interest	-	126.76	43.9	43.9
Shareholders' Equity	122.38	72.11	9.1	15.98
Total Liabilities & Equity	133.23	77.51	10.54	16.76
Total Debt	0.55	0.78	0.16	0.26
Net Cash (Debt)	125.81	72.88	9.83	15.84
Net Cash Growth	72.61%	641.67%	-37.97%	-
Net Cash Per Share	8.29	18.24	2.48	4.07
Book Value	122.38	-54.64	-34.8	-27.92
Book Value Per Share	8.07	-13.67	-8.79	-7.18
Tangible Book Value	122.38	-54.64	-34.8	-27.92
Tangible Book Value Per Share	8.07	-13.67	-8.79	-7.18

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q